Givaudan stock faces price-fixing trial after court ruling

A US federal judge has allowed claims alleging price-fixing by Givaudan and Symrise in fragrance ingredients to move toward a trial. The ruling keeps the litigation active but does not determine whether either company is liable.

According to Bloomberg Law, Judge William J. Martini of the US District Court for the District of New Jersey said the plaintiffs had adequately alleged price-fixing under the Sherman Act and state antitrust laws. He denied the defendants' motion for judgment on the pleadings.

Claims move toward courtroom review

The judge said the alleged conduct should be assessed as horizontal price-fixing, a category involving competitors at the same market level. The decision means the claims can continue through the litigation process and potentially reach trial. It is a procedural ruling on the pleadings, not a finding that Givaudan or Symrise inflated prices.

For Givaudan, the case adds a legal risk to an otherwise operationally focused investor narrative. The company reported nine-month 2026 sales of 5,891 million Swiss francs in October and has highlighted growth in fragrance and beauty alongside a slower Taste & Wellbeing business. The litigation could keep attention on potential costs, remedies and management time as the case develops, although its financial outcome is not established by the ruling.

Givaudan stock traded at 4,382.50 euros on Lang & Schwarz at 12:00 CET on Wednesday, November 11, 2026.

Investors will also watch the company's operating progress and wider Swiss market developments in the current market reports.

Givaudan's next scheduled full-year results are due on January 27, 2027. More news and analyses on Givaudan stock.